Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial.
Nikolas J S LondonRichard S KaiserMohammed Ali KhanRayan A AlshareefMohammed KhuthailaAbtin ShahlaeeAnthony ObeidVanessa A LondonFrancis Char DeCroosOmesh P GuptaJason HsuJames F VanderMarc J SpirnCarl D RegilloPublished in: The British journal of ophthalmology (2018)
The management and prevention of PVR is challenging and complex. At the dose and duration given in this study, oral istotretinoin may reduce the risk of PVR-associated recurrent retinal detachment in eyes with primary RRD at high risk of developing PVR.